APOA2 Antibody

1. Weight loss resulted from a reduction of HDL in both APOE-II genotypes. However, in C homozygote carriers, it was shown that HDL3 reduced significantly and leads to a general shift toward larger size HDL subfractions after intervention, while in T allele carriers HDL2 decreased significantly and weight loss leads to shift toward smaller size HDL subfractions. PMID:28545455
2. There was a statistically significant interaction between APOA2 polymorphism and dietary fatty acids intake on oxidative stress n patients with type 2 diabetes PMID:27271094
3. This study detected a reduced level of heterodimer apoA2-ATQ/AT and a specific apoA2 isoform hypo-processing pattern in the sera of autoimmune pancreatitis patients. PMID:29481802
4. In type 2 diabetes mellitus patients, the dietary intake of antiinflammatory fatty acids, such as omega-3 PUFAs and MUFAs, could reduce the inflammatory effects associated with the Apolipoprotein A2 CC genotype. In addition, proinflammatory fatty acids, such as SFAs, could overcome the antiinflammatory effect of the T-allele. PMID:28359369
5. data support an SR-B1 nibbling mechanism that is similar to that of streptococcal serum opacity factor, which also selectively removes CE and releases apoAI, leaving an apoAII-rich remnant. PMID:28373285
6. A new missense mutation in an Iranian population has a significant association with high-density lipoprotein cholesterol levels. PMID:26590203
7. ApoAII-ATQ/AT not only distinguished the early stages of pancreatic cancer from healthy controls but also identified patients at high risk for pancreatic malignancy. PMID:26549697
8. Plasma apoB pool size of VLDL containing apoA-II is much smaller than that of VLDL without apoA-II, and this was caused by a very low rate of secretion of this VLDL type into plasma. PMID:26071654
9. APOA-II polymorphism and oxidative stress is associated with poor prognosis in patients with type 2 diabetes. PMID:26104730
10. Apolipoprotein AII was detected as a protein associated with the urinary protein/urinary creatinine levels in pediatric idiopathic steroid-sensitive nephrotic syndrome PMID:24633472
11. Apolipoprotein A-II/B significantly improves risk prediction of overall survival, also in carotid surgery patients with lower LDL levels PMID:25953375
12. Apolipoprotein A-II and the regulation of high density lipoproteins in cardiovascular disease. [Review] PMID:24012775
13. We have cloned the cDNA encoding human ApoA-II and achieved its high-level secreting expression with a yield of 65 mg/L of yeast culture PMID:24116940
14. identified a statistically significant interaction between the APOA2 -265T > C variant and higher-fat dairy food intake in the Boston Puerto Ricans and replicated this relation in the GOLDN study PMID:24108135
15. Clinical studies demonstrate that apoA-II is a strong predictor of risk for CVD. There is no evidence, however, that selective therapeutic modification of apoA-II impacts on atherosclerosis and clinical outcomes.[review] PMID:21501035
16. These data suggest Apo-AII-containing high-density lipoproteins (HDL) formed intrahepatically are likely cholesterol-rich compared to the smaller intracellular lipid-poor Apo A-I HDL. PMID:23025327
17. Enrichment of apo A-II in high-density lipoprotein particles has atheroprotective effects and apo A-II may become a target for the treatment of atherosclerosis. PMID:23241412
18. We conclude that apoA-II plays a significant role in apoE-associated risk of incident CVD in women with high levels of HDL-C and CRP. PMID:22723940
19. APOA2 m265 genotype may be associated with eating behaviours and dietary modulation of plasma ghrelin. PMID:21386805
20. a gene-diet interaction involving the APOA2 -265T>C SNP and saturated fat intake determines body weight in a Mediterranean and an Asian populations PMID:20975728
21. Human apolipoprotein A-II inhibits the production of interferon-gamma by concanavalin A-stimulated mouse and human CD4-positive T cells. PMID:21300819
22. Low apolipoprotein-A2 is associated with metastatic renal cell cancer. PMID:20022911
23. ApoA-II plays a crucial role in triglyceride catabolism by regulating lipoprotein lipase activity, at least in part, through HDL proteome modulation. PMID:19910634
24. The serum apoA-II concentrations confer risk for MetS and diabetes and exhibit evidence of anti-inflammatory properties among Turks. PMID:19817643
25. In metabolic syndrome, fenofibrate, but not atorvastatin, influences high density lipoprotein metabolism by increasing the transport of APOA2 particles. PMID:19651918
26. when expressed in transgenic mice, HDL shows antioxidant properties PMID:11971944
27. Overexpression in transgenic mice does not increase their susceptibility to insulin resistance and obesity PMID:12032642
28. Evaluated as a positional candidate gene for familial Type II diabetes, altered lipid concentrations, and insulin resistance PMID:12136402
29. Crystallographic studies of apo A-II and its complex with lipid surrogate beta-octyl glucoside show that disulfide-linked dimers of apo A-II form amphipathic alpha-helices which aggregate into tetramers. PMID:12269810
30. Carriers of a novel splice-site mutation in the LDL-receptor gene were simultaneously homozygous for the -265C variant of apoA-II thus concluding that one variant of the apoA-II gene was associated with reduced plasma LDL cholesterol in FH patients PMID:12522687
31. This protein inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation PMID:12690114
32. Genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia. PMID:12738753
33. Analysis of trancription factors that bind response elements in the apoA-II promotor and modulate transcription. PMID:12959642
34. apoA-II affects both the structure and the dynamic behavior of HDL particles and selectively modifies lipid metabolism PMID:14967812
35. In transgenic mice overexpressing the human apoA-II gene, plasma human apoA-II concentration was positively correlated with blood glucose levels. PMID:14988251
36. this protein-exonic splicing enhancer interaction is able to promote the incorporation of exon 3 in mRNA and suggest that they can rescue the splicing despite the noncanonical 3' splice site. PMID:15247216
37. Overexpressed human apoA-II in mice impairs HDL protection of apoB-lipoproteins from oxidation. Displacement of PON1 by apoA-II may explain why PON1 is found in HDL particles with apoA-I, not apoA-II, & apo-A-II-rich HDL's poor antiatherogenic properties. PMID:15388641
38. results indicate a significant association between the T265C APOA-II polymorphism and levels of visceral adipose tissue in premenopausal women present in white but not African-American women PMID:15833935
39. Characterization of regulatory elements found in the apoA-II exon 3 and its flanking introns that are involved in the control of apoA-II exon 3 splicing. PMID:16254078
40. the association of apoA-II with triglyceride-rich lipoproteins occurs in the circulation and induces postprandial hypertriglyceridemia PMID:16990646
41. ApoA-II adopts a beltlike structure in which the protein helices wrap around the lipid- bilayer reconstituted high density lipoprotein (rHDL) disc. PMID:17264082
42. ApoAII is efficiently reabsorbed in kidney proximal tubules in relation to its plasma concentration PMID:17652309
43. carriers of the minor allele for Apo A-II -265T/C (CC/TC) have a lower postprandial response compared with TT homozygotes PMID:17709437
44. ApoA-II is associated with a decreased risk of future coronary artery disease in apparently healthy people, implying that apoA-II itself exerts effects on specific antiatherogenic pathways. PMID:17923573
45. APOAII rs5082 polymorphism may have a role in reducing risk of coronary artery disease in an Australian male population PMID:18179799
46. results for dimeric apolipoprotein AII are similar to those we have reported for the monomeric apolipoprotein CI, which has a similar secondary structure but a different peptide sequence and net charge PMID:18652418
47. procoagulant activities of plasma factor VIIc and factor Xc are positively and independently associated with concentrations of the high-density lipoprotein apolipoprotein, apo A-II PMID:18766253
48. small sizes (i. e., number of kringle-4 repeats in the gene) of apolipoprotein (a) are risk factors for the development of atherothrombosis. (review) PMID:19069164
49. Results indicate that CETP inhibition increases plasma concentrations of apoA-II by delaying HDL apoA-II catabolism and significantly alters the remodeling of apoA-II-containing HDL subpopulations. PMID:19193611
50. The available data does not support a role for common variants in APOA2 on type 2 diabetes susceptibility or related quantitative traits in Northern Europeans PMID:19216768

Show More

Hide All

HGNC: 601

UNIGENE: Hs.237658

KEGG: hsa:336

STRING: 9606.ENSP00000356969

OMIM: 107670